Search Results - Peter Hirth

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Evaluation of the stability of human erythropoietin in samples for radioimmunoassay

    Evaluation of the stability of human erythropoietin in samples for radioimmunoassay by Kai‐Uwe Eckardt, A. Kurtz, Peter Hirth, P. Scigalla, Lothar Wieczorek, Christian Bauer

    Published 1988
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence Videomicroscopy

    Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence Videomicroscopy by Peter Vajkoczy, Michael D. Menger, Brigitte Vollmar, Lothar Schilling, Peter Schmiedek, K. Peter Hirth, Axel Ullrich, T. Annie T. Fong

    Published 1999
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Inhibition of VEGF receptors causes lung cell apoptosis and emphysema

    Inhibition of VEGF receptors causes lung cell apoptosis and emphysema by Yasunori Kasahara, Rubin M. Tuder, Laimute Taraseviciene‐Stewart, Timothy D. Le Cras, Steven H. Abman, Peter Hirth, Johannes Waltenberger, Norbert F. Voelkel

    Published 2000
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

    Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma by William D. Tap, Ke-Wei Gong, Judy Daring, Yiou Tseng, Charles Ginther, Giovanni M. Pauletti, John A. Glaspy, Richard Essner, Gideon Bollag, Peter Hirth, Chao Zhang, Dennis J. Slamon

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

    Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor by Chao Zhang, Prabha N. Ibrahim, Jiazhong Zhang, Elizabeth A. Burton, Gaston Habets, Ying Zhang, Ben Powell, Brian L. West, Bernice Matusow, Garson Tsang, Rafe Shellooe, Heidi Carias, Hoa Nguyen, Adhirai Marimuthu, Kam Y. J. Zhang, Angela J. Oh, Ryan Bremer, Clarence R. Hurt, Dean R. Artis, Guoxian Wu, Marika Nespi, Wayne Spevak, Paul Lin, K. B. Nolop, Peter Hirth, Greg H. Tesch, Gideon Bollag

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

    Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity by James Tsai, John Tayu Lee, Weiru Wang, Jiazhong Zhang, Hanna Cho, Shumeye Mamo, Ryan Bremer, S. Gillette, Jun Kong, Nikolas K. Haass, Katrin Sproesser, Ling Li, Keiran S.M. Smalley, Daniel W. Fong, Yongliang Zhu, Adhirai Marimuthu, Hoa Nguyen, Billy Lam, Jennifer Liu, Ivana Cheung, Julie Rice, Yoshihisa Suzuki, Catherine A. Luu, Calvin Settachatgul, Rafe Shellooe, John Cantwell, Sung‐Hou Kim, Joseph Schlessinger, Kam Y. J. Zhang, Brian L. West, Ben Powell, Gaston Habets, Chao Zhang, Prabha N. Ibrahim, Peter Hirth, Dean R. Artis, Meenhard Herlyn, Gideon Bollag

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

    Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent by Dean R. Artis, Jack J. Lin, Chao Zhang, Weiru Wang, Upasana Mehra, Mylène Perreault, David V. Erbe, Heike I. Krupka, B.P. England, J. Malcolm O. Arnold, A.N. Plotnikov, Adhirai Marimuthu, Hoa Nguyen, Sarah Will, Maxime Signaevsky, John G. Kral, John Cantwell, Calvin Settachatgull, Douglas S. Yan, Daniel W. Fong, Angela J. Oh, Shenghua Shi, Patrick Womack, Benjamin E. Powell, Gaston Habets, Brian L. West, Kam Y. J. Zhang, Michael V. Milburn, George P. Vlasuk, K. Peter Hirth, K. B. Nolop, Gideon Bollag, Prabha N. Ibrahim, James F. Tobin

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

    Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma by Gideon Bollag, Peter Hirth, James Tsai, Jiazhong Zhang, Prabha N. Ibrahim, Hanna Cho, Wayne Spevak, Chao Zhang, Ying Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Garson Tsang, Brian L. West, Ben Powell, Rafe Shellooe, Adhirai Marimuthu, Hoa Nguyen, Kam Y. J. Zhang, Dean R. Artis, Joseph Schlessinger, Fei Su, Brian Higgins, Raman Iyer, Kurt D’Andrea, Astrid Koehler, Michael Stumm, Paul Lin, Richard J. Lee, Joseph F. Grippo, Igor Puzanov, Kevin B. Kim, Antoni Ribas, Grant A. McArthur, Jeffrey A. Sosman, Paul B. Chapman, Keith T. Flaherty, Xiaowei Xu, Katherine L. Nathanson, K. B. Nolop

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

    Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor by William D. Tap, Zev A. Wainberg, Stephen P. Anthony, Prabha N. Ibrahim, Chao Zhang, John H. Healey, Bartosz Chmielowski, Arthur P. Staddon, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Arun S. Singh, Igor Puzanov, Eunice L. Kwak, Andrew J. Wagner, Daniel D. Von Hoff, Glen J. Weiss, Ramesh K. Ramanathan, Jiazhong Zhang, Gaston Habets, Ying Zhang, Elizabeth A. Burton, Gary C. Visor, Laura Sanftner, Paul Severson, Hoa Nguyen, Marie J. Kim, Adhirai Marimuthu, Garson Tsang, Rafe Shellooe, C. M. Gee, Brian L. West, Peter Hirth, K. B. Nolop, Matt van de Rijn, Henry H. Hsu, Charles Peterfy, Paul Lin, Sandra Tong-Starksen, Gideon Bollag

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: